Sodium-Glucose Transporter 2 Inhibitors: all 1,276 studies that test it
Page 1 of 13. Open to participants first (266), then studies with results posted, then the rest; newest registration first within each.
- Effect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin ResistanceNot yet recruitingNCT07891234Phase 4
- Canagliflozin Plus Progestin for Atypical Endometrial Hyperplasia and Early-Stage Endometrial CancerNot yet recruitingNCT07890064Phase 2
- EMBRACE (EMPA in BReast Cancer for Activity and Cardiac ProtEction)Not yet recruitingNCT07883512Phase 2
- Evaluation of Dapagliflozin and Empagliflozin as Adjunctive Therapy to Methotrexate in Patients With Rheumatoid ArthritisNot yet recruitingNCT07864688Phase 2
- Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 FibrosisRecruitingNCT07848191Phase 4
- A Study in Healthy People to Compare How 2 Different Formulations of Vicadrostat / Empagliflozin Tablets Are Taken up in the BodyRecruitingNCT07845630Phase 1
- The GranStone TrialNot yet recruitingNCT07828002Phase 2/3
- Cardioprotective Effect of Empagliflozin in Breast Cancer PatientsNot yet recruitingNCT07815808Phase 3
- Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary SyndromeNot yet recruitingNCT07810998Phase 2/3
- Neurovascular Effects of EmpagliflozinNot yet recruitingNCT07799441Phase 4
- Metformin-Dapagliflozin Effects on IGF-1 in Male T2DM With MASLDNot yet recruitingNCT07778719Not applicable
- Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEFRecruitingNCT07776054Phase 4
- The Effect of Empagliflozin and Metformin on Oxidative Capacity and Microvascular Reactivity of Skeletal Muscle in Patients With Type 2 Diabetes MellitusRecruitingNCT07771010Phase 4
- Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's DiseaseNot yet recruitingNCT07756294Phase 2
- Timing of Empagliflozin in Primary PCI: Pre-Reperfusion Versus Post-Reperfusion Versus Placebo in South Asian STEMI PatientsNot yet recruitingNCT07749014Phase 2
- aDAPt-ANOCA: Dapagliflozin for the Treatment of Angina With Non-Obstructive Coronary Artery Disease (ANOCA)Not yet recruitingNCT07741890Phase 2
- Dapagliflozin Add-on in Unresectable HCC With Metabolic SyndromeNot yet recruitingNCT07729592Phase 2
- Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive ImpairmentRecruitingNCT07711171Phase 4
- Safety and Efficacy of Canagliflozin in Patients With Locally Advanced or Advanced Solid CancerRecruitingNCT07703163Phase 1
- the Clinical Outcome of Empagliflozin in Pediatric Heart Failure PatientsRecruitingNCT07692256Phase 2
- "Exploring the Potential Benefits of Using Dapagliflozin in Cirrhotic Chronic Liver Disease Patients- A Randomized Controlled Trial"RecruitingNCT07684326Phase 2/3
- SGLT2i Effect on PTDM Development and Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients: A Randomized, Doubleblind, Placebo Controlled, National Multicenter TrialNot yet recruitingNCT07682350Phase 2
- Finerenone and Empagliflozin Combination in Obesity With Hypertension: A 12-Week Prospective, Parallel-design, Double-blind, Randomized, Placebo-controlled TrialNot yet recruitingNCT07678151Not applicable
- A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes MellitusRecruitingNCT07662109Phase 3
- A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes MellitusRecruitingNCT07662044Phase 3
- A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)RecruitingNCT07624305Phase 3
- Ertugliflozin's Effect on Heart Function in Diabetic Patients After Myocardial InfarctionNot yet recruitingNCT07621380Phase 4
- To Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16001 and DWC202518 Compared to DWP16001 Monotherapy and DWC202518 Monotherapy in Patients With Type 2 Diabetes MellitusNot yet recruitingNCT07619833Phase 3
- SGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in DiabetesRecruitingNCT07614230Phase 4
- "Dapagliflozin vs Dapagliflozin-Finerenone for Albuminuria in CKD With Type 2 Diabetes"Not yet recruitingNCT07598864Phase 3
- Precision T1D Platform - New Therapies for Cardio-Renal ComplicationsNot yet recruitingNCT07594145Phase 2
- Sotagliflozin as Prevention of Anthracycline-Related CardiotoxicityNot yet recruitingNCT07572175Phase 2
- Delayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected Aetiology (DELAY-HF), Pilot StudyRecruitingNCT07572032Phase 4
- Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)Enrolling by invitationNCT07547878Phase 4
- Regression in Left Ventricular Hypertrophy and Fibrosis in Aortic StenosisNot yet recruitingNCT07539259Phase 2
- PRECISE Phenotyping to Guide Therapies for Coronary Microvascular DysfunctionNot yet recruitingNCT07533747Phase 3
- CANagliflozin In DIALysis PatientsNot yet recruitingNCT07527390Phase 4
- Dapagliflozin for Anemia in Lower-Risk Myelodysplastic SyndromesNot yet recruitingNCT07516847Phase 2
- Dapagliflozin Effect on Glucose Variability in Patients Post Bariatric SurgeryEnrolling by invitationNCT07515391Phase 2
- Manganese-enhanced Magnetic Resonance Imaging in Takotsubo CardiomyopathyRecruitingNCT07491718Not applicable
- Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.RecruitingNCT07491042Not applicable
- Assessing the Efficacy of Dapagliflozin as a Vasculoprotective Treatment in Septic Shock Patients With Microcirculatory DysfunctionNot yet recruitingNCT07488689Phase 3
- The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan ProcedureRecruitingNCT07482943Phase 4
- SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose MetabolismRecruitingNCT07482020Phase 2
- Empagliflozin Adjunctive Therapy in Bipolar DepressionNot yet recruitingNCT07472920Not applicable
- Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 DiabetesEnrolling by invitationNCT07452913Phase 4
- Glycemic Variability of Combination Therapies in T2DMRecruitingNCT07442006Phase 4
- Ketone Monitoring Approaches for Diabetic Ketoacidosis Risk Mitigation in People With T1D on Adjunctive SGLT-2 InhibitorsNot yet recruitingNCT07421518Phase 2
- Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney DiseaseRecruitingNCT07405216Phase 4
- The Effect of Dapagliflozin on Myocardial Strain in Patients With Acute Heart FailureNot yet recruitingNCT07403955Not applicable
- Add-on Diuretics in Acute Decompensated Heart FailureRecruitingNCT07372040Phase 2
- Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus PatientsNot yet recruitingNCT07365358Phase 4
- CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes in Non-diabetic ACS Patients Without HFNot yet recruitingNCT07351643Phase 4
- Dapagliflozin Versus Metformin for the Management of Antipsychotic-Induced Weight Gain: A Pragmatic Pilot Randomized Controlled TrialNot yet recruitingNCT07342764Phase 4
- Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based TherapyRecruitingNCT07336797Phase 2
- Epicardial Adipose Tissue-Targeted DApagliflozin for Reducing Electrical Remodeling in Atrial FibrillationNot yet recruitingNCT07331727Not applicable
- A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and WarfarinRecruitingNCT07331389Phase 1
- Dapagliflozin in Active Lupus NephritisRecruitingNCT07323524Phase 4
- DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With CirrhosisRecruitingNCT07322237Phase 4
- A Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI)Not yet recruitingNCT07311551Phase 4
- Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate CancerNot yet recruitingNCT07310433Phase 2
- Epicardial Cardiac Fat-CT (EPIC-CT)RecruitingNCT07297589Phase 3
- Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)RecruitingNCT07295223Phase 3
- Effect of Empagliflozin on InflammationRecruitingNCT07292909Phase 4
- STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney DiseaseRecruitingNCT07280585Phase 3
- Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal SyndromeRecruitingNCT07273838Phase 2
- SGLT2 Inhibitors and Survival in Lung Cancer Patients With DiabetesNot yet recruitingNCT07272057Not applicable
- Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetesRecruitingNCT07254572Phase 4
- Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer PatientsRecruitingNCT07245069Phase 2
- Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThyRecruitingNCT07240844Phase 4
- A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney DiseaseRecruitingNCT07239570Phase 4
- Dapagliflozin in DepressionRecruitingNCT07239011Phase 1/2
- Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung AdenocarcinomaRecruitingNCT07235280Early Phase 1
- SGLT2i Therapy in Islet Transplantation (SIT)RecruitingNCT07228195Phase 4
- Evaluating Safe Ketone Thresholds To Minimise Ketosis in People With Type 1 Diabetes Using DapagliflozinNot yet recruitingNCT07225465Phase 2
- SGLT2 Inhibitors in Adult Primary Nephrotic SyndromeRecruitingNCT07214818Phase 2/3
- RECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Dapagliflozin or Usual CareRecruitingNCT07187570Phase 3
- Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver DiseaseNot yet recruitingNCT07180745Phase 4
- Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, EmpagliflozinRecruitingNCT07175051Phase 2
- SGLT2 Inhibitors in Geographic AtrophyRecruitingNCT07174687Phase 2
- Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne CardiomyopathyRecruitingNCT07172971Phase 1
- Role of Finerenone in African American Veterans With Diabetic Kidney DiseaseNot yet recruitingNCT07155694Phase 4
- Empagliflozin as a Potential Therapeutic Solution for Patients With Brugada SyndromeNot yet recruitingNCT07146880Phase 2
- SGLT2i Safety and Efficacy on Kidney Allograft Function in Non-diabetic Kidney Transplant RecipientsRecruitingNCT07143773Phase 4
- SLGT2i for Neuroprotection in Patients With Acute Ischemic StrokeNot yet recruitingNCT07105917Phase 3
- Impact of Dapagliflozin for the Regulation of Immunological Activity in Membranous NephropathyNot yet recruitingNCT07096986Phase 2
- Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and MetforminRecruitingNCT07093476Phase 3
- A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fed)RecruitingNCT07083401Phase 1
- A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting)RecruitingNCT07083388Phase 1
- Safety and Efficacy of Canagliflozin in Patients With Metastatic High Microsatellite Instability (MSI-H) Colorectal CancerRecruitingNCT07076823Phase 1
- Treating the Metabolic Syndrome With a Sodium-glucose Cotransporter-2 InhibitorEnrolling by invitationNCT07065357Phase 3
- Vascular Effects of SGLT2i in Non-diabetic CKDNot yet recruitingNCT07060417Phase 2
- SGLT2i in Kidney StonesRecruitingNCT07055282Early Phase 1
- SGLT2i, Pioglitazone, and Ketone Production in T2DRecruitingNCT07053319Phase 1
- SGLT2i, Ketoacidosis, Volume Contraction, and InsulinopeniaRecruitingNCT07053306Phase 1
- SGLT2i, Hepatic Glucose Production, and SNSRecruitingNCT07053293Early Phase 1
- Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart FailureRecruitingNCT07038356Phase 3
- SGLT-2 Inhibitors on Albuminuria in Chronic Kidney Disease Patients With Lupus Nephritis and ANCA- Associated VasculitisNot yet recruitingNCT07035834Phase 4
- Dapagliflozin for Cardio-renal Protection After ICU DischargeRecruitingNCT07025629Phase 3
- Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy ToxicityRecruitingNCT07018622Phase 2